Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Flatt

Showing results (51-60 of 325) with videos related to

Pageof 33
Sort By:
Diabetes & Vascular Disease Research|December 13, 2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetesBrian D Green, Peter R Flatt, Clifford J Bailey
Expert Opinion on Emerging Drugs|August 31, 2006
Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetesBrian D Green, Peter R Flatt, Clifford J Bailey
Diabetes, Obesity & Metabolism|January 19, 2021
Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?Galyna V Graham, Chris M McLaughlin, Peter R Flatt
Biological Chemistry|August 20, 2011
Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in ratsNigel Irwin, Jacqueline M E Francis, Peter R Flatt
Peptides|March 13, 2025
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbiditiesClifford J Bailey, Peter R Flatt, J Michael Conlon
Expert Review of Endocrinology & Metabolism|October 6, 2018
Effects of anti-diabetic drugs on bone metabolismGuillaume Mabilleau, Daniel Chappard, Peter R Flatt, et al.
Peptides|January 6, 2024
Recent advances in peptide-based therapies for obesity and type 2 diabetesClifford J Bailey, Peter R Flatt, J Michael Conlon
Molecular and Cellular Endocrinology|January 7, 2020
Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db miceFinbarr P M O'Harte, Vadivel Parthsarathy, Peter R Flatt
Acta Diabetologica|January 8, 2016
G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasisBrian M Moran, Peter R Flatt, Aine M McKillop
International Journal of Molecular Sciences|May 14, 2025
The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell LineageWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Pageof 33

Showing results (51-60 of 325) with videos related to

Sort By:
Pageof 33
Diabetes & Vascular Disease Research|December 13, 2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetesBrian D Green, Peter R Flatt, Clifford J Bailey
Expert Opinion on Emerging Drugs|August 31, 2006
Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetesBrian D Green, Peter R Flatt, Clifford J Bailey
Diabetes, Obesity & Metabolism|January 19, 2021
Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?Galyna V Graham, Chris M McLaughlin, Peter R Flatt
Biological Chemistry|August 20, 2011
Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in ratsNigel Irwin, Jacqueline M E Francis, Peter R Flatt
Peptides|March 13, 2025
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbiditiesClifford J Bailey, Peter R Flatt, J Michael Conlon
Expert Review of Endocrinology & Metabolism|October 6, 2018
Effects of anti-diabetic drugs on bone metabolismGuillaume Mabilleau, Daniel Chappard, Peter R Flatt, et al.
Peptides|January 6, 2024
Recent advances in peptide-based therapies for obesity and type 2 diabetesClifford J Bailey, Peter R Flatt, J Michael Conlon
Molecular and Cellular Endocrinology|January 7, 2020
Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db miceFinbarr P M O'Harte, Vadivel Parthsarathy, Peter R Flatt
Acta Diabetologica|January 8, 2016
G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasisBrian M Moran, Peter R Flatt, Aine M McKillop
International Journal of Molecular Sciences|May 14, 2025
The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell LineageWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Pageof 33